01—Abstract
Summary
Summary of the 10-Q filed October 31, 2023. Cited figures are marked; the original filing is the authoritative source.
GE HealthCare Technologies Inc. (GEHC) reported a 5% increase in total revenues for the third quarter of 2023, reaching $4.82 billiona, and a 7% increase for the first nine months, totaling $14.35 billion.
This growth was driven by strong performance across most segments, particularly Pharmaceutical Diagnostics (PDx) and Patient Care Solutions (PCS), with notable contributions from supply chain improvements and price increases. Despite revenue growth, net income attributable to GE HealthCare declined by 23%b for the quarter and 14% year-to-date, primarily due to a significant increase in interest and other financial charges stemming from new debt issuances and the Term Loan Facility. The company also saw increased operating expenses related to its transition to a standalone entity and planned investments in R&D.
Financially, GEHC ended the quarter with $2.42 billionc in cash and cash equivalents. The company's long-term borrowings increased to $10.25 billion.
While operating income remained stable year-over-year for the nine-month period, the significant increase in interest expenses impacted profitability. The company's guidance and outlook suggest continued revenue growth, but investors should monitor the impact of rising interest costs on net income and the company's ongoing investments in innovation and operational efficiency.
02—Key points
Key Highlights
- Total revenues increased by 5% to $4.82 billion in Q3 2023 and by 7% to $14.35 billion for the first nine months of 2023, driven by broad-based segment growth.
- Organic revenue growth was strong at 6% for Q3 and 9% for the nine-month period, indicating solid underlying business performance.
- Net income attributable to GE HealthCare decreased by 23% in Q3 and 14% year-to-date, primarily due to higher interest expenses and increased operating costs.
- Interest and other financial charges increased significantly, by $136 million in Q3 and $393 million year-to-date, due to new debt obligations.
- Operating income remained stable year-over-year for the nine-month period at $1.75 billion, but net income margin compressed due to increased expenses.
- The company ended the period with $2.42 billion in cash and cash equivalents, providing a solid liquidity position.
- Remaining Performance Obligations (RPO) stood at $14.16 billion as of September 30, 2023, indicating a strong future revenue pipeline, although down slightly from the prior year.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2023, GE HealthCare Technologies Inc. kept $0.08.
- Revenue$4.82B100.0%
- Cost of revenue−$2.89B59.9%
- Gross profit$1.94B40.1%
- Operating costs−$1.32B27.3%
- Operating income$617.0M12.8%
- Interest, other & tax−$242.0M5.0%
- Net income$375.0M7.8%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2023filed October 31, 2023Financial Statements
Q3 FY2023 against Q3 FY2022
| Line item | Q3 FY2023Q3 FY2022 | Change |
|---|---|---|
| Revenue | $4.82B$4.58B | +5.4% |
| Gross Profit | $1.94B$1.77B | +9.1% |
| R&D Expenses | $322.00M$260.00M | +23.8% |
| SG&A Expenses | $996.00M$908.00M | +9.7% |
| Operating Expenses | $1.32B$1.17B | +12.8% |
| Operating Income | $617.00M$605.00M | +2.0% |
| Net Income | $375.00M$487.00M | −23.0% |
| EPS (Basic) | $0.82$1.07 | −23.4% |
| EPS (Diluted) | $0.82$1.07 | −23.4% |
| Shares Outstanding (Basic) | 455.00M454.00M | +0.2% |
| Shares Outstanding (Diluted) | 458.00M454.00M | +0.9% |
05—Questions
Frequently Asked Questions
What were the main drivers of revenue growth in the third quarter?
Revenue growth in the third quarter of 2023 was primarily driven by a 5% increase in total revenues to $4.82 billion. This growth was fueled by broad-based segment performance, particularly in Pharmaceutical Diagnostics (PDx) and Patient Care Solutions (PCS), supported by improvements in supply chain fulfillment and strategic price increases across various product lines.
Why did net income attributable to GE HealthCare decrease despite revenue growth?
Net income attributable to GE HealthCare decreased by 23% in the third quarter ($375 million) and 14% year-to-date ($1.17 billion) compared to the prior year. This decline was largely due to a significant increase in 'Interest and other financial charges – net,' which rose by $136 million in the quarter and $393 million year-to-date. This increase is attributed to interest expenses related to debt securities issued in late 2022 and the Term Loan Facility drawn in early 2023. Additionally, operating expenses, including SG&A and R&D investments related to the company's standalone operations, also contributed to the margin pressure.
What is the company's current financial position and liquidity outlook?
GE HealthCare ended the third quarter of 2023 with a healthy cash and cash equivalents balance of $2.42 billion. The company has access to significant revolving credit facilities totaling $3.5 billion. Management believes that its current cash position, projected operating cash flows, and access to capital markets are sufficient to meet its operational and financial obligations for at least the next 12 months, providing a stable liquidity outlook.
How has the company's debt structure changed, and what is the impact?
GE HealthCare's long-term borrowings increased significantly to $10.25 billion as of September 30, 2023, from $8.23 billion at the end of 2022. This increase is primarily due to the issuance of senior unsecured notes and the drawdown of a Term Loan Facility in connection with its separation from GE. While this provides capital for operations and investments, the associated interest expense has become a material factor impacting profitability, as evidenced by the sharp increase in 'Interest and other financial charges – net.'
06—Continue